NEW EVIDENCE IN TYPE 2 INFLAMMATION ACROSS ASTHMA, CRSwNP, EOSINOPHILIC ESOPHAGITIS, AND ATOPIC DERMATITIS

Join Dr William Busse and Dr Oscar Palomares as they share the latest evidence connecting IL-4 and IL-13, key and central drivers of type 2 inflammation, to downstream consequences including barrier and tissue dysfunction, dysregulation of gene expression, type 2 biomarkers, and pathologic and clinical features observed in asthma, CRSwNP, atopic dermatitis, and eosinophilic esophagitis to clinical outcomes across type 2 inflammatory diseases.

Oscar Palomares, PhD
Spain

Unifying the Heterogeneous Pathophysiology of Type 2 Inflammatory Diseases

WATCH SESSION

William Busse, MD
United States

The Spectrum of Type 2 Inflammatory Diseases and the Associated Burden

WATCH SESSION

THE TYPE 2 EXPERIENCE: EXPLORING THE CLINICAL BURDEN AND UNDERLYING TYPE 2 INFLAMMATION IN SEVERE ASTHMA PATIENTS

Join Dr Andrea Matucci and Dr Ian Pavord as they discuss the role of type 2 inflammation in uncontrolled asthma, its impact on lung function, and the cumulative burden of coexisting type 2 inflammatory airway diseases.

Andrea Matucci, PhD
Italy

Type 2 Inflammation Underpins the Pathophysiology and Clinical Outcomes of Uncontrolled Asthma

WATCH SESSION

Ian Pavord, MBBS, DM, FRCP, FMedSci
United Kingdom

A Closer Look at the Clinical Burden of Uncontrolled Asthma and the Impact of Coexisting Type 2 Inflammatory Diseases

WATCH SESSION

CRSwNP, A TYPE 2 INFLAMMATORY DISEASE: PAST, PRESENT, AND FUTURE PERSPECTIVES

Join Dr Stella Lee and Dr Martin Wagenmann as they translate underlying type 2 inflammation in CRSwNP to the clinical burden of disease and discuss the cumulative burden of coexisting CRSwNP and other type 2 inflammatory airway diseases.

Stella Lee, MD
United States

The Role of Type 2 Inflammation in the Pathophysiology of CRSwNP

WATCH SESSION
<

Martin Wagenmann, MD
United States

Clinical Burden of CRSwNP and the Compounding Impact of Coexisting Type 2 Diseases

WATCH SESSION